Drug
Savolitinib clinical trials
Also written AZD6094, HMPL-504 and Volitinib.
Keep track of what changes. Save the savolitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
41 studies that test it; most in 2019 (6)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 16
AstraZeneca (15) · Hutchison Medipharma Limited (9) · National Cancer Institute (NCI) (3) · Samsung Medical Center (3) · Hutchmed (1) · Canadian Cancer Trials Group (1) · Assistance Publique Hopitaux De Marseille (1) · Guangdong Association of Clinical Trials (1)
Often tested with
Tested in the same studies.
Durvalumab (7) · Osimertinib (4) · Docetaxel (4) · Crizotinib (2) · Pyrotinib (2) · Adavosertib (1) · Darolutamide (1) · Ocifisertib fumarate (1)
Studies
Open first, then newest update. How each study uses savolitinib is read from its arms, and is right about nine times in ten.
Testing it · 41
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Savolitinib
- Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)RecruitingPhase 2Jeeyun LeeNCT05620628Written as Savolitinib
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491Written as Savolitinib
- Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET OverexpressionRecruitingPhase 1/2The First Affiliated Hospital of Guangzhou Medical UniversityNCT05777278Written as Savolitinib
- Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingPhase 3AstraZenecaNCT05043090Written as savolitinib
- Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCActive, not recruitingPhase 3HutchmedNCT05009836Written as Savolitinib
- Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCActive, not recruitingPhase 2AstraZenecaNCT05374603Written as Savolitinib
- Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentActive, not recruitingPhase 3AstraZenecaNCT05261399Written as Savolitinib
- Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03598244Written as Savolitinib
- A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCActive, not recruitingPhase 2AstraZenecaNCT04606771Written as Osimertinib + Savolitinib
- Savolitinib vs. Sunitinib in MET-driven PRCC.Active, not recruitingPhase 3AstraZenecaNCT03091192Written as Savolitinib
- Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationCompletedPhase 3Hutchison Medipharma LimitedNCT05015608Written as Savolitinib + Osimertinib
- Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma PatientsCompletedPhase 2Hutchison Medipharma LimitedNCT04923932Written as Savolitinib
- Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruitingPhase 2Canadian Cancer Trials GroupNCT03385655Written as Savolitinib
- A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy VolunteersCompletedPhase 1AstraZenecaNCT06348355Written as [11C]savolitinib
- Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsCompletedPhase 3Hutchison Medipharma LimitedNCT04923945Written as Savolitinib
- Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedCompletedPhase 2National Cancer Institute (NCI)NCT02761057Written as Savolitinib
- MEDI4736 Combinations in Metastatic Renal Cell CarcinomaCompletedPhase 2Queen Mary University of LondonNCT02819596Written as Savolitinib
- Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceActive, not recruitingPhase 2Assistance Publique Hopitaux De MarseilleNCT03833440Written as Savolitinib
- Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLCActive, not recruitingPhase 2Guangdong Association of Clinical TrialsNCT05163249Written as Savolitinib
See all 41 studies that test savolitinib →
Given in every arm · 2 — savolitinib is usual care beside what is tested
- Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibActive, not recruitingPhase 2AstraZenecaNCT03778229Written as savolitinib
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingPhase 2AstraZenecaNCT03944772Written as Savolitinib
Codes
What other systems call savolitinib · ClinicalTrials.gg INT000122
- MeSH (NLM) C0005932591-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazineConfirmed NLM, Wikidata
- UNII (FDA) 2A2DA6857RSAVOLITINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27254463savolitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C104732SavolitinibOne source FDA
- DrugBank DB12048One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000593259 | 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine | Confirmed NLM, Wikidata |
| UNII (FDA) | 2A2DA6857R | SAVOLITINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27254463 | savolitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C104732 | Savolitinib | One source FDA |
| DrugBank | DB12048 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.